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Regulation of inducible nitric oxide synthase expression in rat mesang-
ial cells and isolated glomeruli. The presence of the inducible isoform of
nitric oxide synthase (iNOS) in glomerular mesangial cells facilitates the
synthesis of nitric oxide (NO) after stimulation with cytokines or lipopoly-
saccharide (LPS). As the role of NO within the glomerulus may be
important in conditions such as glomerulonephritis, we have studied the
effect of dexamethasone (DX) and pirrolidine dithiocarbamate (PDTC),
an inhibitor of the nuclear transcription factor, NF-KB activation on the
induced synthesis of NO in rat mesangial cells (RMC). LPS, tumor
necrosis factor-alpha (TNF-a) and the combination of both were able to
induce NO synthesis in a dose-dependent manner as measured with the
determination of NO2— levels. Treatment with LPS (10 .rgIm1) + TNF-a
(100 nglml) for eight hours was the most potent stimulus for iNOS activity.
DX (1 tM) had an inhibitory effect on LPS-, TNF-a- and LPS +
TNF-a-induced NO synthesis (51.2, 42.5 and 68% of inhibition, respec-
tively). The inhibitory effect of DX was confirmed using a reporter cell
bioassay, whereas cGMP was measured as a reflection of bioactive NO.
DX inhibited induced NO synthesis when RMC were exposed to this agent
before (16 hr of pretreatment, 75.7% inhibition) or at the same time (8 hr
of cotreatment, 61.2% inhibition) as TNF-a + LPS but not four hours
after the stimuli. Northern blot analysis showed marked blunting of
mRNA expression in RMC treated with DX, in concordance with
functional studies. Both actinomycin D and cycloheximide significantly
inhibited NO synthesis and iNOS mRNA expression. PDTC (100 /.LM) was
able to inhibit the iNOS activity induced by LPS and TNF-a independently
(56.8 and 49.9% inhibition, respectively), and in combination (79.1%
inhibition). PDTC (1 to 100 I.tM) inhibited LPS + TNF-a-induced NO
synthesis and iNOS mRNA expression in a concentration-dependent
fashion (69 to 86% inhibition of NO synthesis and 50 to 100% inhibition
of mRNA expression). Addition of PDTC four hours after exposure to
TNF-a + LPS was still able to markedly inhibit NO synthesis. The effects
of DX and PDTC were also demonstrated in isolated glomeruli, where
two different combinations of inductive stimuli for NO synthesis were
employed. Our results establish DX and PDTC as useful tools to study the
regulation of NO synthesis in the mesangial cell and glomerulus, and
suggest that NF-KB is involved in the transcriptional regulation of iNOS in
RMC.
Mesangial cells are modified vascular smooth muscle cells in
the renal glomerulus which participate in the regulation of
glomerular filtration rate and macromolecular trafficking [1].
They are also crucial targets in several renal pathophysiological
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conditions [2] and are known to possess an inducible isoform of
nitric oxide synthase. This enzyme catalyzes the conversion of
L-arginine into L-citrulline and nitric oxide after the stimulation
with cytokines or microbial wall products [3—5]. There are exper-
imental data showing that glomeruli synthesize NO in diverse
models of experimental glomerulonephritides [6—8], although its
pathophysiological role and source are still under discussion.
Recently, Shultz and Raij suggested that endogenous production
of NO could play a role in the prevention of endotoxin-induced
glomerular thrombosis [9, 10]. Thus, the regulation of glomerular
iNOS becomes an important issue with potential implications in
clinical situations such as septic shock [10].
The role of the ubiquitous messenger NO [11, 12] in the many
tissues where it has been found is varied and dependent on the
generator and effector cell types. The availability of cDNAs
encoding for the different isoforms [13—15] made possible the
correlation of their presence with functional studies, and hence
almost every cell type or tissue synthesizing NO is associated with
the expression of either a constitutive or an inducible isoform of
nitric oxide synthase (cNOS or iNOS), with the probable excep-
tion of endothelial cells which may express both isoforms [16—18].
Initial work in rat mesangial cells showed their ability to synthe-
size NO under the influence of lipopolysaccharide and/or cyto-
kines [3—5] and characterized the regulation exerted on this
phenomenon by anti-inflammatory steroids and transforming
growth factor-f3 [19, 201. However, few studies have pursued the
potential mechanisms involved in this regulation or correlated
functional activity of iNOS with mRNA expression. In this work
we have analyzed the effect of dexamethasone (DX), a well-
known glucocorticoid anti-inflammatory agent, on the inhibition
of iNOS in stimulated RMC, and studied its correlation with
iNOS mRNA expression. Our interest in understanding regula-
tory pathways of NO synthesis in RMC led us to hypothesize that
NF-KB, a nuclear transcription factor involved in the regulation of
the expression of a plethora of genes related to inflammatory
responses [21], could represent a potential transcriptional modu-
lator of mesangial iNOS. In this study we have used an inhibitor
of NF-KB activation with antioxidant properties, pirrolidine di-
thiocarbamate (PDTC) [22], as a tool to explore this hypothesis,
and we provide data suggesting that NF-KB is involved in the
transcriptional regulation of iNOS. Furthermore, we have ex-
tended these studies to isolated glomeruli and demonstrated an
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inhibitory effect of DX and PDTC on NO synthesis and iNOS
mRNA expression.
Methods
Materials
Recombinant human tumor necrosis factor-alpha (rHuTNF-a,
9.8 x 106 U/mg) was a gift of Knoll Pharmaceuticals (Whippany,
NJ, USA); recombinant murine interferon gamma (rM11IFN-'y,
io U/mg) was from Genzyme (Cambridge, MA, USA); cell
culture media were from Bio-Whittaker (Walkersville, MD,
USA), fetal calf serum and media supplements were from ICN-
Flow (High Wycombe, UK); cell culture plates were from Costar
(Cambridge, MA, USA); Taq polymerase was from Promega
(Southampton, UK) and dNTPs from Gibco, BRL (Middlesex,
UK); deoxycytidine 5 '-triphosphate [a-32P] (3000 Ci/mmol) was
from Amersham (Aylesbury, UK); guanosine 3'5'-cyclic mono-
phosphate radioimmunoanalysis kit was from Biomedical Tech-
nologies Inc. (Stoughton, MA, USA). All other reagents including
lipopolysaccharide E. coli strain 055:B5, dexamethasone and
pirrolidine dithiocarbamate (PDTC) were from Sigma Chemical
(St. Louis, MO, USA).
Glomerular isolation and cell culture
Rat mesangial cells and renal glomeruli were obtained and
characterized as described [23, 24]. Cells were used in primary
culture between 14 and 21 days after seeding or after one passage.
They were cultured in 100 mm plates or 50 ml flasks with 5% CO2
and fed every 48 hours with RPMI 1640 supplemented with 15%
fetal calf serum, L-glutamine (1 mM), penicillin (50 U/ml), and
streptomycin (50 j.g/ml). RFL-6 cells, an established rat fetal lung
fibroblast line, were obtained from American Type Culture Col-
lection (ATCC CCL 192) and cultured as described [171. Potential
toxicity of reagents on RMC was ruled out by trypan blue
exclusion (> 90% of cells were viable) and measurements of LDH
release to the cell culture media (data not shown).
Incubation procedure
On the day of the experiment, cells were washed twice with
RPMI devoid of phenol red, as this compound may interfere with
NO2 - spectrophotometric measurement, and left in their usual
medium except for the absence of serum and phenol red. Con-
fluent plates of RMC were incubated with the different reagents
as described for each experiment. At the end of the experiment
supernatants were collected for N02 measurements and cells
from these same plates were used for RNA isolation as described
below. Isolated glomeruli (aliquots of °1 to 2 X iO glomeruli/
plate) were placed in RPM! 1640 devoid of phenol red supple-
mented with HEPES 15 m, sodium pyruvate (110 mg/liter),
glucose (3.5 g/liter), penicillin (50 U/ml) and streptomycin (50
tg/ml) at 37°C during the experimental protocol. At the end of
each experiment supernatants were collected for N02 measure-
ments and RNA was isolated from whole glomeruli.
N02 determination
This procedure was based on the Griess reaction [25]. After
completing the experimental protocol, 200 1d of culture superna-
tant were mixed with an equal volume of Griess reagent (0.1%
N-(1-naphthyl)ethylenediamine in water; 1% sulfanilamide in 5%
phosphoric acid, 1:1) and the absorbance was read at 540 nm.
N02 concentration was determined using sodium nitrite as a
standard. Samples of RPMI 1640 that had not been exposed to
mesangial cells were assayed for background levels of N02 and
these values were substracted from the values measured in the cell
culture media.
RNA isolation and Northern blot analysis
Total cellular RNA was isolated from RMC with the guani-
dinium thiocyanate-phenol-chloroform method [26], size-frac-
tionated by electrophoresis (10 j.g/lane) through denaturing 1%
agarose-0.66 M formaldehyde gels, transferred to Hybond hybrid-
ization transfer membranes (Amersham, UK), and UV cross-
linked before hybridization as previously described [18]. As initial
hybridizations using the full length eDNA from murine macro-
phage iNOS eDNA (MAC-NOS, gift of Drs. Lowenstein and
Snyder) [27] resulted in a high background, a 700 bp fragment was
obtained using the polymerase chain reaction (PCR) and the
following primers: sense: 5' GAG AGA TCC GAT TTA GAG
TCT 3'; antisense 5' GCA GAT TCT GCT GGG ATT TCA 3'.
PCR was performed for 35 cycles, each consisting of one minute
at 94°C, one minute at 55°C and one minute at 72°C. After
validation with Southern blot analysis using MAC-NOS as a probe
it was labeled with [a-32P1 dCTP using a commercial kit for
random hexamer labeling (Boehringer Mannheim, Germany) and
used as a probe for Northern analysis. Hybridization was per-
formed at 42°C for 12 to 16 hours, membranes were then washed
at final stringency conditions of 55°C, 0.2 x SSC, 0.1% SDS and
exposed on XAR Kodak film, using an intensifying screen. In
order to correct for uneven loading and to make sure differences
in mRNA expression were specific for iNOS, every blot was
stripped and rehybridized with rat -actin [281. However, because
TNF-a has been shown to destabilize f3-actin mRNA in some
systems [291, we performed Northern blot analysis of -actin
mRNA expression in RMC treated with TNF-s at 0, 4, 8 and 24
hours. In these experimental conditions, we were unable to find
significant differences in the expression of this gene in RMC (N =
2, data not shown). Densitometric analysis was performed on an
Apple scanner using Image 1.3.1 (NIH, Bethesda, MD, USA).
Results are expressed in arbitrary units as the ratio of iNOS/-
actin expression.
RFL-6 assay and cGMP quantitation
This procedure was based on the protocol described by Ishii et
al [30] with slight modifications [31]. In this assay, the NO
synthesized by a donor monolayer, RMC in this case, is sensed by
a reporter cell monolayer, RFL-6 cells. NO is able to activate its
natural ligand, soluble guanylate cyclase, and therefore changes in
intracellular cGMP levels accurately reflect the amounts of NO
generated by the donor cells. For this purpose RMC were
cultured in flasks and RFL-6 cells in six-well dishes. At the end of
the incubation period cells were placed on a 37°C water bath so
that only the monolayers were in contact with the water. After a
10-minute equilibration period RMC were washed twice and left
with 2 ml Locke's buffer (in mM:154 NaC1, 5.6 KC1, 10 Hepes, 2
CaC12, 1 MgC12 6H2O, 3.6 NaHCO3 and 5.6 glucose) with 1 mM
L-arginine. Superoxide dismutase (SOD) was added at a final
concentration of 100 U/mI, RFL-6 cells were washed twice and
left with 0.8 ml Locke's buffer with 3-isobuthyl-1-methylxanthine
(IBMX) (0.3 mt final). After another 10 minutes, 0.8 ml condi-
tioned medium from each flask of RMC were transferred to the
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Table 1. LPS and TNF-a-induced NO synthesis in rat mesangial cells
(RMC)
N02
Treatment Concentration nmol/106 cells
Control — 4.09 0.4
LPS pglml 0.1 4.38 0.34
LPS jgIml 1 8.76 0.25a
LPS pg/mI 10 8.86 0.4a
TNF-a nglml 0.1 4.22 0.1
TNF-a nglml 1 9.42 1.8
TNF-a ng/ml 10 10.74 0.8
TNF-o ng/ml 100 13.13 0.la
RMC were incubated with vehicle (Control), LPS and rHuTNF-a for 8
hours at the concentrations shown above. N02 levels were determined as
described. Data represent the mean SE of 4 independent experiments
with each condition duplicated per experiment.
P < 0.05 vs vehicle
RFL-6 cells and left for three minutes. At the end of this period,
the medium was aspirated, 1 ml of 0.1 N HC1 was added and cells
were placed on ice for 20 minutes. Samples were then recovered
and neutralized with 20 1.d of 5 M NaOH and 20 id of 5 M sodium
acetate and kept at —20°C. Quantitation of RFL-6 cGMP content
was performed with a commercial radioimmunoassay.
Statistical analysis
Every experimental condition was duplicated within each ex-
periment and each experiment was performed, at least three
times. Comparisons were made with analysis of variance followed
by Dunnett's modification of the t-test whenever comparisons
were made with a common control and the unpaired two-tailed
Student's t-test for other comparisons. This test was used when-
ever the number of total observations allowed to and after
performing a Kolmogorov-Smirnov test to confirm the normal
distribution of the data. When the number of observations was
insufficient to perform adequate parametric tests, non-parametric
tests were employed (Kruskal-Wallis). The level of statistically
significant difference was defined as P < 0.05.
Results
Dexamethasone inhibits NO production in rat mesangial cells
stimulated with LPS, TNF-q, and the combination of both
As both LPS and TNF-a had been shown to induce NO
synthesis in mesangial cells [3, 5, 32] we explored the isolated and
combined effect of these agents in RMC. Table 1 shows the effects
of LPS and TNF-a on NO synthesis, measured as the N02 level
in RMC. Both compounds were able to significantly stimulate the
synthesis of NO. In several experiments (N = 3 to 7) we were able
to confirm that LPS induced NO synthesis approximately two- to
fourfold, TNF-a two- to threefold and the combination of both at
the highest concentrations shown for each of one, three- to sixfold
(data not shown). Hence, the concentrations of 10 sg/ml for LPS
and of 100 ng/ml for TNF-a were selected for the combined use
of these agents in the rest of the experiments. Time course
experiments using TNF-a and LPS simultaneously (LIT) were
then performed. Although after four hours of treatment with LIT
a significantly higher amount of NO2 was observed compared to
control (0 hr, 5.28 1.3; 4 hr, 16.91 0.4 nmol/106 cells), a
maximum was reached after eight hours of treatment, with no
further significant increment in the amount of N02 levels
Table 2. Dexamethasone (DX) inhibits the LPS, TNF-a and LPS/TNF-
induced NO synthesis in rat mesangial cells (RMC)
Treatment
N02 nmo1/106 cells
NA DX 8 hr
CT
LPS
TNF-a
LPS + TNF-a
3.47 0.77
10.88 0.06a
11.22 1.92a
17.29 0.29°
ND
6.86 0.74k'
7.92 0.03°
9.16 047d
RMC were incubated with vehicle (CT, 8 hr), LPS (10 pg/mI, 8 hr),
rHuTNF-a (100 ng/ml, 8 hr) and LPS + TNF-a (8 hr) in the absence (NA)
or presence of DX (10—6 M, 8 hr). N02 levels were determined as
described. Data represent the mean SE of 3 independent experiments
with each experimental condition duplicated per experiment. ND is not
done.
° P < 0.05 vs. vehicle
P < 0.05 vs. LPS
P < 0.05 vs. TNF-adP < 0.05 vs. LPS + TNF-a
determined after 24 hours (8 hr, 27.6 0.6; 24 hr, 30.7 1.2
nmolll0° cells; N = 4). Thus, eight hours was selected as the
period of stimulation with L/T for experiments concerning regu-
lation of NO synthesis and iNOS expression.
We then explored the potential effect of DX on NO synthesis in
RMC. Table 2 shows the effect of DX on N02 levels in RMC
treated with TNF-cs, LPS and TNF-a + LPS. DX was able to
inhibit the effect induced by TNF-a, LPS and L/T on NO
synthesis. In several experiments described later, DX was unable
to modify basal NO synthesis as studied with determination of
N02 or cGMP levels in a reporter cell assay.
NO2and nitrate (NO3—) represent higher redox states of NO
and their accumulation is widely accepted as a reflection of NO
synthesis [33]. However, whether or not this NO is biologically
active has not been established. Therefore, in order to confirm the
effect of DX on NO synthesis in RMC, a coincubation bioassay
with RFL-6 cells was used as described in Methods. Figure 1
depicts the effect of DX on LPS + TNF-a (LIT)-induced NO
synthesis in RMC. DX clearly abrogated (>90%) the expected
LIT-induction (4-fold) of NO synthesis without modifying basal
values (N = 2). These results closely paralleled the observations
made with the determination of N02 levels. For this reason we
have used this latter method in order to evaluate the activity of
iNOS in RMC.
Incubation of stimulated RMC (LPS 10 gIml, 8 hr +
rHuTNF-a 100 ng/ml, 8 hr) with two different NOS antagonists,
L-NMA (NGmethylLarginine, 500 tM, 8 hr) and L-NNA (Nw-
nitro-L-arginine, 500 .LM, 8 hr), in separate experiments, com-
pletely abolished LPS + TNF-a-induced NO production (data not
shown; N = 2).
Figure 2 shows the concentration and time dependence of the
DX inhibitory effect. Pretreatment with DX significantly inhibited
NO synthesis at two of the three concentrations tested (10 nM, 100
n and I LM, 25.4 5.9, 58.4 8.4 and 74.2 3.6% of inhibition,
respectively, compared to induction by LPS + TNF-a after
subtracting control values, N = 6). Only 16 hours of pretreatment
or eight hours of cotreatment of RMC with DX had a significant
inhibitory effect. As shown in Figure 2B, when DX was added four
hours after LPS + TNF-a, N02 levels were lower than stimu-
lated ones, but did not reach statistical significance.
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DX+L/T
Fig. 1. Effect of dexamethasone (DX) on iNOS activity in rat mesangial cells
(RMC). Cells were incubated with vehicle (CT, 24 hr), LPS (10 sgiml, 8
hr) + rHuTNF-a (100 nglml, 8 hr) (LIT), DX (10- M, 24 hr) and DX
(10—6 M, 24 hr) + L/T (8 hr). In this experimental procedure cGMP levels
are determined using RFL-6 as reporter cells. Medium from RMC was
transferred to RFL-6 cells in the presence of superoxide dismutase (SOD)
(20 mm, 100 U/mI). RFL-6 cells were incubated for 3 mm with conditioned
medium from RMC exposed to the different treatments in the presence of
0.3 mM IBMX. Columns represent the mean SE of 3 independent
experiments with each experimental condition duplicated per experiment,
*P < 0.05 vs. vehicle, t P < 0.05 vs. LIT.
DX decreases iNOS mRNA expression in RMC stimulated with
LPS + TNF-cx
To explore the mechanism by which stimulation of N02 levels
takes place, Northern blot analysis of total RNA from RMC was
performed. As shown in Figure 3A, LPS + TNF-a induced the
expression of a 4.5 Kb transcript which corresponds to iNOS. No
other bands were detected in these experiments, suggesting high
specificity of the probe employed. This expression was blunted by
DX (106 M) about 50%, an effect which was also concentration-
dependent (control, 0.20 0.09; LIT, 4.86 0.64; DX 10—6 +
LIT, 1.87 0.09; DX iO + LIT, 2.65 0.21; DX i0 LIT,
2.53 0.45 relative densitometric units; N = 3; Fig. 3A).
Densitometric analysis of Northern blots showed that the DX
inhibitosy effect on iNOS expression was more powerful when it
was added before (16 hr) than at the same time (8 hr) or after (4
hr) the addition of LPSITNF-a (control, 0.30 0.10; LiT, 5.1
0.64; DX 24 hr + LIT, 0.94 0.06; DX 8 hr + LIT, 2.61 0.13;
DX 4 hr LIT, 3.08 0.45 relative densitometric units; N = 3;
Fig. 3B), in concordance with the results obtained with N02
measurements.
Nitric oxide synthesis induced by LPS + TNF-a in RMC is
dependent on protein and mRNA synthesis
As we were interested in establishing potential regulatory
mechanisms for iNOS expression in RMC, we investigated
whether or not NO synthesis and iNOS expression were depen-
dent on protein and mRNA synthesis. Cycloheximide (CX) (10
gIml, 8 hr), a well-known protein synthesis inhibitor, and acti-
nomycin D (Act D) (10 .tg/ml, 8 hr), an inhibitor of RNA
synthesis, significantly blocked N02 production in RMC stimu-
lated by LIT (vehicle, 6.1 0.6; LIT, 21.6 0.4; CX + L/T, 9.2
0.1; ActD + LIT, 12.4 0.1 nmolIlO6 cells; P < 0.05 for vehicle
CT DX LIT L/T+ L/T+ LIT+
DX24hrDX8hr DX4hr
Fig. 2. Concentration and time dependence of dexamethasone (DX) inhibi-
tion on LPS/TNF-a-induced NO synthesis in rat mesangial cells (RMC). A.
RMC were incubated with vehicle (CT, 24 hr), LPS (10 g/ml, 8 hr) +
rHuTNF-cs (100 nglml, 8 hr) (LIT), DX (10—6 M, 24 hr) and DX (24 hr) at
different concentrations (10_c, iO— and io_ M) + L/T (8 hr). N02
levels were determined as described. Columns represent the mean SE of
6 independent experiments with each experimental condition duplicated
per experiment. * P < 0.05 vs. vehicle; t P < 0.05 vs. LIT. B. RMC were
incubated with vehicle (CT, 24 hr), LPS (10 gglml, 8 hr) + rHuTNF-a
(100 ng/ml, 8 hr) (LIT), DX (10-6 M, 24 hr) and DX (10—6 M) at different
times (24, 8 and 4 hr) + L/T (8 hr). NO2levels were determined as
described. Columns represent the mean SE of 4 independent experi-
ments with each experimental condition duplicated per experiment. * P<
0.05 vs. vehicle; t P < 0.05 vs. LIT.
vs. LIT, LIT vs. CX+LIT, and LIT vs. ActD + L/T; N 5). CX
and ActD did not significantly modify basal N02 levels (data not
shown). This effect was closely paralleled by iNOS expression in
RMC (control, 0.32 0.03; LIT, 5.01 0.15; CX 10 + LIT, 0.86
0.4; CX I + LIT, 3,28 1.16; Act D + LIT, 0.20 0.06 relative
densitometric units; N = 3; Fig. 4).
Pyrrolidine dithiocarbamate (PDTC) inhibits stimulated nitric
oxide synthesis in rat mesangial cells stimulated with LPS, TNF-q,
and the combination of both
In an effort to identify transcriptional regulatory mechanisms
implicated in the expression of RMC iNOS, we studied the role of
NF-iB in the activation of iNOS transcription. As shown in Table
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3, PDTC, a relatively specific inhibitor of NF-KB activation [22],
significantly blunted NO2 production by RMC after treatment of
these cells with LPS, TNF-a and the combination of both. This
inhibition was dependent on the concentration but was clearly
significant with the three concentrations tested (1, 10 and 100 M,
69.4 18.9, 79.8 8.1 and 86.6 8.1% inhibition, respectively,
of LPS + TNF-a-induced NO synthesis after subtracting control
values, N = 4; Fig. 5A). Both pretreatment for 16 hours and
simultaneous cotreatment (8 hr) with PDTC markedly abrogated
N02 production (91.5 9.5 and 82.5 16.6% respectively, N =
4; Fig. SB). However, in contrast with DX, PDTC was still able to
significantly inhibit N02 production when RMC were exposed to
this agent four hours after LPS + TNF-a stimulation (61 8.9%
of inhibition, N = 4; Fig. 5B). PDTC alone did not significantly
modify basal N02 levels (Fig. 5).
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Pyrrolidine dithiocarbamate (PDTC) inhibits iNOS mRNA
expression in rat mesangial cells stimulated with LPS and TNF-cx
Northern blot analysis also demonstrated that pretreatment
with PDTC was able to completely blunt iNOS mRNA expression
in stimulated RMC (Fig. 6), an effect which was also concentra-
tion-dependent (control, 0.39 0.1; LiT, 8.02 0.1; PDTC 100 +
LIT, 0.4 0.06; PDTC 1 + LIT, 1.79 0.03 relative densitometric
units; N = 3). PDTC alone did not modify basal N02 levels or
mRNA expression.
Whole isolated glomeruli treated with LPS + cytokines synthesize
NO and express iNOS and this synthesis and expression is
abrogated by DX and PDTC
As shown in Table 4 isolated glomeruli were able to synthesize
NO after stimulation with LPS + TNF-a or LPS + IFN-y. We
BA \A\\\\, \, \,
q,x .\X q,X
NOS
4.5 Kb
fI-actin
1.8 Kb
INOS
4.5 Kb
fI-actin
1.8 Kb
ci,
C
CT L/T DX L/T+ L/T+ L/T+
DX 10-6 DX 1 0 DX 1 08
Fig. 3. Effect of dexamethasone (DX) on iNOS mRNA expression in rat mesangial cells (RMC) stimulated with LPS + TNF-cc. Northern blot analysis of
total RNA (10 jtgllane) from RMC probed with a 700 bp fragment of MAC-iNOS. An iNOS transcript (4.5 Kb) was clearly visible in RMC treated with
LIT. Expression of rat /3-actin in the same membrane is shown in the middle half of the panel and the densitometric analysis of the iNOS Northern blot
corrected for 3-actin expression is shown below. A. RMC were treated with vehicle (CT, 24 hr), LPS (10 igIml, 8 hr) + rHuTNF-a (100 nglml, 8 hr)
(LIT), DX (10—6 M, 24 hr) and DX (106 to 108 M, 24 hr) + LIT (8 hr). B. RMC were incubated with vehicle (24 hr), LPS (10 Wml, 8 hr) + rHuTNF-a
(100 nglml, 8 hr) (LIT), DX (106 M, 24 hr) and DX (106 M, 24, 8 and 4 hr) + L/T (8 hr). Shown are representative data of three independent
experiments.
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Table 3. Pirrolidine dithiocarbamate (PDTC) inhibits LPS, TNF-a and
LPS + TNF-a-induced NO synthesis in rat mesangial cells (RMC)
Treatment
N02 nmo1/106 cells
NA PDTC 8 hr
CT 3.47 0.77 ND
LPS 10.88 0.06a 6.67 0.56"
TNF-a 11.22 1.92a 7.35 o.oic
LPS + TNF-a 17.29 0.29a 6.77 047d
RMC were incubated with vehicle (CT, 8 hr), LPS (10 g/ml, 8 hr),
rHuTNF-a (100 ng/ml, 8 hr) and LPS + TNF-a (8 hr) in the absence (NA)
or presence of PDTC (100 LM, 8 hr). NO2— levels were determined as
described. Data represent the mean sit of 3 independent experiments
with each experimental condition duplicated per experiment. ND is not
sc\> (3c)#
<c.x' \>
A.,X
x
iNOS
4.5 Kb
done.
a p < 0.05 vs. vehicle
-actin b P < 0.05 vs. LPScp < 0.05 vs. TNF-a1.8 Kb dp <0.05 vs. LPS + TNF-a
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CxlO Cxl ActD
Fig. 4. Effect of cycloheximide (CX) and actinomycin D (Act D) on iNOS
mRNA expression in rat mesangial cells (RMC) stimulated with LPS --
TNF-cr Northern blot analysis of total RNA (10 gg/lane) from RMC
probed with a 700 bp fragment of MAC-iNOS. Expression of rat /3-actin
in the same membrane is shown in the middle half of the panel and the
densitometric analysis of the iNOS Northern blot corrected for 13-actin
expression is shown below, RMC were incubated with vehicle (CT, 24 hr),
LPS (10 sg/ml, 8 hr) + rHuTNF-a (100 ng/ml, 8 hr) (L/T), CX (10 jsg/ml,
8 hr), Act D (10 sg/ml, 8 hr), CX (1 and 10 sg/ml, 8 hr) + L/T and Act
D (10 tg/ml, 8 hr) + L/T. Shown are representative data of three
independent experiments.
observed that the combination of LPS + IFN-y was more potent
than LPS + TNF-a (4.5-fold vs. 2-fold), in contrast with results
obtained in RMC where the two combinations were equally
potent (data not shown). Also in this case, DX and PDTC clearly
inhibited N02 production (Table 4), an effect again paralleled by
iNOS expression (control, 1 0.01; LIT, 2.78 0.46; L/IF, 5.04
0.11; DX + LIT, 0.68 0.05, DX + LIIF, 1.55 0.01; PDTC +
LIT, 0.23 0.08; PDTC + LITF, 0.18 0.06 relative densitometric
units; N 4; Fig. 7).
Our study addresses potential pathways of regulation of iNOS
expression in RMC. The induced synthesis of NO in mesangial
cells is a well established fact at least in three different species
[3—5, 34]. We have demonstrated that DX and PDTC directly
inhibit iNOS activity and expression in RMC treated with TNF-a,
LPS and a combination of both. Furthermore, we believe this is
one of the first reports which suggests the participation of a
transcription factor, NP-KB, in the activation of iNOS in RMC.
Finally we have extended our studies to isolated glomeruli in an
effort to correlate our findings with histologically more complex
structures but probably more suited for pathophysiological inter-
pretations.
The fact that CX and Act D inhibited iNOS activity and mRNA
expression in RMC is consistent with current concepts of INOS
regulation in other tissues, including rat vascular smooth muscle
cells [35], which, given their common mesenchymal origin, one
would predict to behave in a similar fashion as RMC. Two different
groups have recently described that cycloheximide is able to induce
the expression of INOS in vascular smooth muscle cells and macro-
phages [36, 37]. Cycloheximide may increase the levels of inducible
mRNAs in several ways [38], including the inhibition of the
synthesis of an mRNA destabilizing factor, the stabilization of
polysome-associated mRNAs, the inhibition of the synthesis of a
transcriptional inhibitor, and the influence on the activity of
nuclear protein kinases that may activate transcription factors.
Whether some or all of these effects take place according to cell
or species differences remains to be established. Our results are in
agreement with reports from other groups who studied regulation
of iNOS by cycloheximide in different cell types [35, 39, 40].
Although the concentrations employed in our study may be
regarded as high, significant toxicity was excluded by cell viability
and enzyme release studies.
The time course exhibited by the DX-induced inhibition of
iNOS suggests that this agent needs to be present for a long
period of time in order to inhibit iNOS expression. In this sense,
DX was unable to abrogate NO production when cells had already
been exposed to LPS + rHuTNF-a for four hours. This implies
that it may act on an event which is proximal to the transcriptional
activation of iNOS and possibly other genes related to inflamma-
tory responses. This may help to understand why, in clinical trials
of DX aimed to evaluate its therapeutic role in situations such as
septic shock, it might not represent a useful agent, as its admin-
istration should precede the clinical expression of sepsis [411.
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Fig. 5. Concentration and time dependence of pirolidine dithiocarbamate(PDTC), inhibition on LPS/TNF-a-induced NO synthesis in rat mesangial
cells (RMC). A. RMC were incubated with vehicle (CT, 24 hr), LPS (10
jig/mI, 8 hr) + rHuTNF-a (100 ng/ml, 8 hr) (L/T), PDTC (100 p.M. 24 hr)
and PDTC (1 to 100 jiM, 24 hr) + LIT (8 hr). N02 levels were
determined as described. Columns represent the mean SE of 4 inde-
pendent experiments, with each experimental condition duplicated per
experiment. *P < 0.05 vs. vehicle; P < 0.05 vs LIT. B. RMC were
incubated with vehicle (24 hr), LPS (10 p.g/ml, 8 hr) + rHuTNF-a (100
nglml, 8 hr) (LIT), PDTC (100 jiM, 24 hr) and PDTC (100 jLM) at 24, 8 and
4 hr + LIT (8 hr). N02 levels were determined as described. Columns
represent the mean SE of 4 independent experiments, with each
experimental condition duplicated per experiment. < 0.05 vs. vehicle;
tP < 0.05 vs. LIT.
Fig. 6. Effect of pirrolidine dithiocarbamate (PDTC) on iNOS mRNA
expression in RMC stimulated with LPS + rHuTNF-a. Northern blot
analysis of total RNA (10 jig/lane) from RMC probed with a 700 bp
fragment of MAC-iNOS. Expression of rat /3-actin in the same membrane
is shown in the middle half of the panel and the densitometric analysis of
the iNOS Northern blot corrected for /3-actin expression is shown below.
RMC were incubated with vehicle (CT, 24 hr), LPS (10 jig/mI, 8 hr) +
rHuTNF-a (100 ng/ml, 8 hr) (LIT), PDTC (100 jiM, 24 hr) and PDTC (100
p.M and I jiM, 24 hr) + LIT (8 hr). Shown are representative data of three
independent experiments.
macrophages [45] and RMC [19] and with reports showing the
effect of DX on iNOS mRNA expression in rat hepatocytes [39].
Among the potential candidates for the regulation of iNOS
transcriptional activation we considered NF-KB. This nuclear
factor regulates the expression of multiple genes in inflammatory
responses of eukaryotic organisms [21]. Carefully conducted
studies have shown that dithiocarbamates are potent inhibitors of
NF-KB activation in intact cells [22]. Their mechanism of action is
probably related to both their dual capability as metal chelators
and strong antioxidants, their molecular action being related with
the inhibition of the release of 1K-B from the rest of the
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Whether DX destabilizes iNOS message or inhibits newly tran-
scribed mRNA remains to be elucidated. Available promoter
analysis of iNOS in macrophages does not show an apparent 5'
glucocorticoid response element [42, 43]. This fact suggests that
DX could have an alternative mechanism of inhibition, such as an
intermediate transregulatory acting element or intracellular alter-
ation of protein synthesis or signal transduction pathways, which
remain to be explored. Interestingly, a similar phenomenon has
been described in relation with the transcriptional activation of
endothelial-leukocyte adhesion molecule (ELAM-1) [44]. Our
results are in agreement with previous functional studies in
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Table 4. Dexamethasone (DX) and pirrolidine dithiocarbamate
(FDTC) inhibit LPSITNF-a- and LPS/IFN-y-induced NO synthesis in
isolated glomeruli
Treatment
NO2 nmol/102 glomeruli
PDTCNA DX
Control 2.0 0.1 2.0 0.2 2.4 0.3
L/T 4.2 0.9a 2.8 0.5" 2.7 0.1"
L/IFN •s 06a6 5.1 1.4c 3.6 1.3c
Aliquots of 1 to 2 x io glomerulilplate were incubated with vehicle
(control, 24 hr), LPS (10 xg/ml, 24 hr) rHuTNF-a (100 ng/ml, 24 hr)
(LiT), LPS (10 .tglml, 24 hr) + rMuIFN-y (100 U/mI, 24 hr) (L/IFN), DX
+ LIT, DX + L/IFN, PDTC + L/T and PDTC + L/IFN (same
concentrations as above, 24 hr). NO2 levels were determined as de-
scribed. Values represent the mean 5E of 3 independent experiments,
duplicate determinations.
a P < 0.05 vs. vehicle
"P < 0.05 vs. UT
P C 0.05 vs. L/IFN
cytoplasmic NF-xB complex, thus preventing its translocation to
the nucleus and subsequent binding to DNA [22]. Our results in
RMC evidence that NF-xB may be involved in iNOS gene
activation as treatment with PDTC inhibited both iNOS expres-
sion and activity. This is in agreement with recent observations
made in other cell types [46, 47]. Although two consensus
sequences for NF-xB binding have been recently described in the
promoter region of the iNOS gene in mouse macrophages [42, 43]
and NF-KB interaction with the iNOS promoter has proven to be
a potential mechanism for transcriptional activation [48], other
mechanisms cannot be excluded. First of all, iNOS eDNA from
RMC has not been cloned or characterized, nor has its promoter
region. Although most probably it will be encoded by the same
gene as the macrophage and vascular smooth muscle isoforms [27,
49—51] this remains to be stablished. Second, NF-.cB seems to be
involved in the activation of genes by reactive oxygen intermedi-
ates (ROI) [52], and PDTC is an agent with proven antioxidant
activity. Participation of these mediators in the cascade of cyto-
kine activation in RMC has been described [53] and therefore this
potential pathway of PDTC intervention cannot be totally ex-
cluded. Of note, gene transcription and expression of vascular cell
adhesion molecule-i (VCAM-1) in human endothelial cells is
regulated by an antioxidant-sensitive mechanism [54], thus sug-
gesting that transcription of genes encoding for inflammation-
related molecules could share common features. Although our
data are consistent with the effect of PDTC on iNOS transcrip-
tional activation, the time course exhibited by the PDTC inhibi-
tion was somewhat surprising. Treatment of RMC with PDTC
after four hours of stimulation was still able to significantly
abrogate LPS + TNF-a-induced NO synthesis, suggesting that
PDTC is also able to act on a post-transcriptional level of iNOS
activation. Studies directed towards promoter analysis of iNOS in
RMC, including deletions of specific consensus sequences for the
potential NF-xB cis-regulatory region, should be able to confirm
and extend these observations.
Intracellular signaling pathways of LPS and TNF-cx responsible
for iNOS activation are not well defined. It is well accepted that
activation of macrophages by LPS results in release of numerous
potent immune mediators, including TNF-cr and NO [55]. Protein
tyrosine phosphorilation has been suggested as a mechanism for
macrophage activation with LPS [56]. Other investigators have
"C) U
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Fig. 7. Effect of DX and PDTC on iNOS mRNA expression in isolated rat
glomeruli stimulated with LPS + rHuTNF-a or LPS + recombinant murine
interferon-',' (rMuIFN-y). Northern blot analysis of total RNA (10 ig/lane)
from isolated rat glomeruli probed with a 700 bp fragment of MAC-iNOS.
Expression of rat j3-actin in the same membrane is shown in the middle
half of the panel and the densitometrie analysis of the iNOS Northern blot
corrected for Ø-actin expression is shown below. Glomeruli were incu-
bated with vehicle (CT, 24 hr), DX (10— 6 M, 24 hr), PDTC (100 LM, 24 hr),
LPS (10 ,aglml, 24 hr) + rHuTNF-a (100 ng/ml, 24 hr) (LiT), UPS (10
gglml, 24 hr) + rMuIFN-y (100 U/ml, 24 hr) (L/IFN), Dx + L/T, DX +
L/IFN, PDTC L/T and PDTC + L/JFN (all at the above concentrations,
24 hr). Shown are representative data of three independent experiments.
found that 0-proteins could differentially regulate two distinct
biochemical pathways in mouse macrophages, one facilitating the
synthesis of TNF-a and the other one of NO [57]. TNF-a alone is
able to trigger the expression of inflammatory molecules through
protein kinase C-dependent and -independent pathways [56, 58].
In RMC both LPS- and TNF-cs-induced NO synthesis was indi-
vidually inhibited by DX and PDTC. Even when these two agents
are known to act on different pathways [22, 59] recent observa-
tions suggest that there might be interaction between the glu-
cocorticoid receptor and NF-icB [60, 61], which is also recognized
as a common target for LPS and TNF-a [21]. Thus, and in
agreement with our results, it seems reasonable to suggest, at the
present level of complexity, that both LPS and TNF-a and DX
and PDTC could use differential and common stimulatory and
inhibitory pathways, respectively, responsible for the regulation of
iNOS.
Mesangial cells are intermingled inside the glomerulus in an
i i iii r 1 11
iNOS
4.5 Kb
-actin
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strategic position to exert regulatory functions of macromolecular
trafficking and ultrafiltration surface. However, it is the whole
glomerulus which represents a structure-function unit and is the
target of several forms of acute and chronic disease. For this
reason, we were interested in demonstrating the synthesis of NO
and expression of iNOS in isolated glomeruli, which are histolog-
ically complex structures, where the relevance of any finding more
closely reflects the in vivo situation. The results obtained in whole
isolated glomeruli are qualitatively similar and consistent with
those obtained in RMC. In the former, however, a different
combination of cytokines (IFN-y + LPS) was more potent than
the one shown in RMC. Although it is certain that RMC are
responsible for part of the NO synthesized by isolated glomeruli,
we cannot exclude the participation of glomerular endothelial
cells or resident macrophages, which, as proposed by Cattell et al,
would be the main source of NO production in inflammatory
conditions such as glomerulonephritis [8]. Cytokine sensitivity of
this alternative cellular source of NO synthesis is predictably
different and has been demonstrated in a murine macrophage cell
line [40], thus offering a reasonable explanation for our results.
Hence, the regulatory effect of DX and PDTC on induced NO
synthesis in isolated glomeruli further reinforces the observations
obtained in RMC and suggests potential pathways of therapeutic
intervention in the cascade of events present in the renal dysfunc-
tion of sepsis.
We believe our study contributes to clarify the mechanism of
glucocorticoid inhibition of iNOS in RMC and incorporates new
information regarding regulation of the iNOS gene by transcrip-
tion factors, namely NF-KB.
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Note added in proof
While this work was under review, two different groups reported similar
effects of dexamethasone (Shultz et al, Kidney mt 46:683—689, 1994) and
pirrolidine dithiocarbamate (Eberhart et al, Biochem Biophys Res Comm
200:163—170, 1994) on the regulation of nitric oxide synthesis in rat
mesangial cells.
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